HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALOXI Capsules safely and effectively. See full prescribing information for ALOXI. ALOXI (palonosetron HCl) Capsules

First Page		Document Content
Date: 2014-09-19 13:52:13 Antiemetics Oncology Prodrugs Ketones Palonosetron Chemotherapy-induced nausea and vomiting 5-HT3 antagonist Eisai Dolasetron Medicine Chemistry Organic chemistry		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALOXI Capsules safely and effectively. See full prescribing information for ALOXI. ALOXI (palonosetron HCl) Capsules Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 372,19 KB Share Document on Facebook

	Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th DocID: 1uZFZ - View Document
	To Whom It May Concern, October 13, 2017 Taisho Pharmaceutical Co., Ltd. Eisai Co., Ltd. Toyama Chemical Co., Ltd. DocID: 1ugwQ - View Document
	11. Major R&D Pipeline In-House R&D Pipeline List Additional Indication, etc.** Product Name / Development Code DocID: 1sXjF - View Document
	ご使用に際して、この説明書を必ずお読みください。また、必要な時に読めるよう大切に保管してください。メコバラミン主薬製剤第3類医薬品 DocID: 1sWWa - View Document
	June 17, Koishikawa, Bunkyo-ku, Tokyo Eisai Co., Ltd. Director, Representative Corporate Officer and CEO Haruo Naito Dear shareholders: DocID: 1siNy - View Document